Bio-Rad Laboratories (NYSE:BIO.B) Sees Large Volume Increase
Bio-Rad Laboratories (NYSE:BIO.B) Sees Large Volume Increase
Bio-Rad Laboratories, Inc. (NYSE:BIO.B – Get Rating) saw unusually-high trading volume on Thursday . Approximately 200 shares traded hands during trading, an increase of 2,757% from the previous session's volume of 7 shares.The stock last traded at $467.95 and had previously closed at $467.95.
Bio-Rad Laboratories, Inc.（紐約證券交易所代碼：BIO.B — 獲取評級）週四的交易量異常高。交易期間約有200股交易，較前一交易日的7股交易量增加了2,757％。該股最後一次交易價格爲467.95美元，此前收於467.95美元。
Analyst Ratings Changes
分析師評級變化
Separately, TheStreet raised shares of Bio-Rad Laboratories from a "d+" rating to a "c-" rating in a report on Monday, March 27th.
另外，TheStreet在3月27日星期一的一份報告中將Bio-Rad Laboratories的股票評級從 “d+” 上調至 “c-” 評級。
Bio-Rad Laboratories Stock Performance
Bio-Rad 實驗室股票表現
The company has a market capitalization of $13.85 billion, a PE ratio of -3.85 and a beta of 0.66. The business's 50-day moving average is $443.89 and its 200-day moving average is $414.16. The company has a debt-to-equity ratio of 0.12, a quick ratio of 4.29 and a current ratio of 5.55.
該公司的市值爲138.5億美元，市盈率爲-3.85，beta值爲0.66。該公司的50天移動平均線爲443.89美元，其200天移動平均線爲414.16美元。該公司的債務與權益比率爲0.12，速動比率爲4.29，流動比率爲5.55。
Bio-Rad Laboratories (NYSE:BIO.B – Get Rating) last issued its earnings results on Thursday, February 16th. The company reported $3.31 earnings per share (EPS) for the quarter. The business had revenue of $730.29 million during the quarter. Bio-Rad Laboratories had a negative net margin of 129.66% and a positive return on equity of 4.59%.
Bio-Rad Laboratories（紐約證券交易所代碼：BIO.B — 獲取評級）最後一次發佈財報是在2月16日星期四。該公司報告了本季度每股收益（EPS）3.31美元。該業務在本季度的收入爲7.3029億美元。Bio-Rad Laboratories的負淨利潤率爲129.66％，正股本回報率爲4.59％。
Bio-Rad Laboratories Company Profile
Bio-Rad 實驗室公司簡介
(Get Rating)
（獲取評級）
Bio-Rad Laboratories, Inc manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.
Bio-Rad Laboratories, Inc 在美國、歐洲、亞洲、加拿大和拉丁美洲生產和分銷生命科學研究和臨床診斷產品。該公司通過生命科學和臨床診斷部門運營。生命科學部門開發、製造和銷售一系列用於研究技術、生物製藥生產過程和食品測試製度的試劑、設備和實驗室儀器。
Featured Articles
精選文章
- Get a free copy of the StockNews.com research report on Bio-Rad Laboratories (BIO.B)
- How to Invest in Central Bank Digital Currency
- Kellogg Company Looks GRRR-eat! At These Levels
- PacWest, First Horizon Shares Plummet On Continued Bank Worries
- Yum! Brands Pulls Back To More Appetizing Levels
- Is it Time for Qualcomm to Start Playing Catch-up?
- 免費獲取 StockNews.com 關於 Bio-Rad 實驗室 (BIO.B) 的研究報告
- 如何投資中央銀行數字貨幣
- Kellogg 公司看起來吃了 GRR-eat！在這些級別
- 由於銀行持續擔憂，PacWest、First Horizon股價暴跌
- 好極了！品牌回落到更具吸引力的水平
- 現在是高通開始追趕的時候了嗎？
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
每天接收 Bio-Rad 實驗室的新聞和評級 -在下面輸入您的電子郵件地址，即可通過Marketbeat.com的免費每日電子郵件時事通訊接收Bio-Rad Laboratories及相關公司的最新新聞和分析師評級的簡明每日摘要。
譯文內容由第三人軟體翻譯。